TGR BioSciences Announces Distribution Partnership with Cedarlane Corporation

For Immediate Release: Adelaide, South Australia, 13th December 2010.

TGR BioSciences, a leading global provider of advanced cell based assay technologies in the fields of cancer, kinase and GPCR research, is extremely pleased to announce a distribution partnership with Cedarlane Laboratories of Burlington, ON, Canada, a leading supplier of Life Science research reagents in North America.

Cedarlane will become a distributor of TGR's new ELISA-One™ technology assay reagents in Canada and the US. The first 20 ELISA-One™ immunoassay kits for cellular phosphoprotein detection will be available from early 2011, with further additions to the portfolio coming soon after.

"We're extremely pleased to be partnering with such a renowned and trusted company as Cedarlane", says Leanna Read, CEO and Managing Director of TGR BioSciences. "Cedarlane is recognized for providing the highest quality products to the Life Science community and we're very confident that Cedarlane will provide an extremely effective means to reach our customers". "Our new ELISA-One™ assays represent a next generation improvement on what is a traditional workhorse technology in Life Science research laboratories around the world", continues Dr. Read, "It's a familiar technology but one with significant advantages over current ELISAs".

"The ELISA-One™ phosphoprotein assay reagents from TGR will complement very well the quality products that Cedarlane has gained a reputation for carrying for the research community", says Michael DeCosimo, General Manager at Cedarlane. "We see an increasing trend and need for high performance, and yet affordable and simple assays such as ELISA-One™, that address the ever more complex questions that Cell Biology researchers face today".

ELISA-One™ Cellular Phosphoprotein Assays

ELISA-One™ cell based immunoassays for phosphoprotein detection are geared towards researchers and cell biologists investigating G-protein coupled receptors and kinases, and cell signaling events in cancer, diabetes, inflammation and many other diseases. ELISA-One™ offers considerable time savings, is remarkably easy to perform and even allows investigators to measure multiple different analytes on a single plate. The assays can be run in as little as 1 hour, only require a single wash and provide an extremely sensitive means for quantitation of endogenously expressed phosphoproteins in cell lysates. Furthermore, there is no requirement for specialized instrumentation, with the assays using standard laboratory plate readers for signal detection.

About Cedarlane Corporation:

Cedarlane is a wholly owned Canadian company, located in Burlington, Ontario, and has been supplying high quality research reagents to the Life Science research community since 1957. Compliant with ISO 9001 and ISO 13485 standards, Cedarlane is committed to providing the utmost in quality products,

service and support to research scientists and laboratories in Canada, the US and worldwide. Cedarlane offers access to products from over 1000 Life Science companies from a single consolidated and trusted source.

About TGR BioSciences:

TGR BioSciences Pty Ltd (TGR) is a fast growing and innovative private biotechnology company based in Adelaide, South Australia, specializing in the development of drug discovery technologies and products to serve the global research and discovery markets for the Life Sciences. TGR provides the highest performing and sensitive cell based assays for analysis of GPCRs, kinases and cell signaling pathways to major pharmaceutical and biotechnology companies, and clients in government funded and academic laboratories worldwide. TGR already has on market a broad portfolio of state-of-the-art assays for cell-based screening used in high-throughput discovery and target identification of novel bioactives. TGR's ELISA-One™ is a newly developed, fast and simple assay technology for the lower throughput research market, initially focused on phosphoprotein detection in cells, and available through distributors from early 2011. TGR is actively developing further novel cell based analysis technologies to advance research in areas such as oncology, neuroscience and other key therapeutic areas.

For more information, please visit www.tgrbio.com

TGR BioSciences contact:

TGR BioSciences
Graham Long
Director of Marketing & Business Development
Tel: +1 (978) 417-9790
Email: glong@tgrbio.com